NatureKue CardioSupport
Ingredients:
• Premium Heart Health Formula (T101), active ingredients: Radix Astragali (as Astragalus Extract), Proprietary Blended Extract, Radix Salviae Miltiorrhizae (as Dan Shen), Radix Notoginseng (as Tienchi Ginseng), Lignum Dalbergiae Odoriferae (as Jiang Xiang).
• Inactive Other Ingredients: Vegetarian capsules (hydroxypropyl methylcellulose), purified water.
• DOES NOT CONTAIN: Wheat, nuts, gluten, sugar, soy, corn, yeast, milk, shellfish.
Direction:
• Take one (1) capsule twice daily with a meal.
• For best results, recommend taking daily for at least three (3) months.
Caution:
• For adults only.
• Consult your healthcare professional if you have any medical conditions or use any medications.
• Stop use if you have allergic reactions towards NatureKue CardioSupport or its ingredients. Do not use if you are pregnant, attempting to become pregnant, or if nursing.
• READ the entire label before use. KEEP THIS OUT OF REACH OF CHILDREN. • Do not use it if the safety seal is damaged or missing. Store in a dry place at room temperature.NatureKue CardioSupport with QiushenYiqi (T101) May Promote Heart Health Daily!
Everything you do is based on the continuous cycle of energy usage and replenishment through your blood flow and microcirculation.
One KEY TO HEART HEALTH
Synergistic compounds in T101, notably QishenYiqi, may improve blood circulation, help increase exercise tolerance.
QishenYiqi is supported by more than 30 patents and clinical trials that demonstratesafety and/or efficacy
Scientific Evidence, read more about QishenYiqi (T101)
A Study of QishenYiqi (T101) in Healthy Participants
Study Type: Interventional (Clinical Trial)
Enrolled 36 participants
Ages Eligible for Study: Age 18 to 50
Study Date from September 21, 2020 to January 11, 2021.
Randomized, Double-blind, Multicenter, Placebo-controlled.
This study is a randomized, double-blind, placebo-controlled, dose-escalation design study, including three cohorts and 36 healthy participants. Within each cohort, participant will receive QishenYiqi at the selected dose level by oral administration three times a day for 28 consecutive days.
Conclusion:Evaluated the safety and tolerability of QishenYiqi in healthy participants.
Trial registration: clinicaltrials.gov:NCT04471298
Clinical Assessment of Complementary Treatment With QishenYiqi (T101)(QSYQ) on Ischemic Heart Failure (CACT-IHF) A Randomized, Double-blind, Multicenter, Placebo-controlled Trial
Study Type: Interventional (Clinical Trial)
Enrolled 640 participants
Ages Eligible for Study: Age 40 to 79
Study Date from March 2012 to August 2014.
Randomized, Double-blind, Multicenter, Placebo-controlled.
640 patients with IHF were enrolled. Randomly assigned to receive 6 months of QSYQ or placebo in addition to standard treatment.
The primary outcome was 6 min walking distance in 6 months.
Conclusions: Treatment with QSYQ for 6 months in addition to standard therapy improved exercise tolerance of IHF patients and was well tolerated.
Trial registration: clinical trials.gov: NCT01555320
Keywords: 6-minute walking test, Ischemic heart failure
Effects of QishenYiqi (T101) in Reducing Myocardial Injury and Preserving Microvascular Function in Patients Undergoing Elective Percutaneous Coronary Intervention: A Pilot Randomized Study
Objective: To evaluate the effect of treatment with QishenYiqi (QSYQ) on myocardial injury and myocardial microvascular function in patients undergoing elective percutaneous coronary intervention (PCI).
Methods: Eighty (80) patients undergoing elective PCI were randomly assigned to QSYQ and control group.
The QSYQ group received QSYQ at a dosage of 0.5 g 3 times daily (3-7 days before PCI and then daily for 1 month) and regular medication, which comprised of aspirin, clopidogrel, statin, β-blocker, and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker in the absence of contradiction.
The control group received only the regular medication. The index of microcirculatory resistance (IMR) was measured at maximal hyperemia after PCI.
Conclusions: The present study demonstrated the benefit of QSYQ in reducing myocardial injury and preserving microvascular function during elective PCI.
Keywords: herbs, microvascular impairment, myocardial injury, percutaneous coronary intervention
QishenYiqi (T101) (QSYQ) for ischemic heart failure: A protocol for a prospective cohort study
It is a multicenter, prospective, observational cohort study.
A total of 1,200 patients with IHF recruited from 84 hospitals.
Assigned to exposure group (patients with QSYQ treatment) or non-exposed group (patients without QSYQ treatment) mainly according to patients' preference in real clinical situation.
The primary outcomes include New York Heart Association (NYHA) cardiac functional classification and Minnesota Living with Heart Failure Questionnaire (MLHFQ).
The secondary outcomes include composite outcomes (all-cause mortality, frequency of re-admission or emergency due to cardiovascular events), left ventricular ejection fraction and cardiothoracic ratio, symptoms and signs obtained by the Tradiational Chinese Medicine (TCM) diagnostic methods. Assessments will be performed at baseline, 1st and 3rd month after enrollment.
Conclusion:It provides new evidence on QSYQ for IHF in real clinical practice.
Trial registration: trialsearch.WHO.int: ChiCTR-ONRC-14004407
Clinical Efficacy and Safety of QishenYiqi (T101) Combined with Conventional Western Medicine in the Treatment of Chronic Heart Failure: A Systematic Review and Meta-Analysis
Objective: The systematic review was designed to evaluate the safety and efficacy of QishenYiqi combined with conventional western medicine in the treatment of chronic heart failure (CHF).
Methods: Relevant randomized controlled trials (RCTs) investigating the clinical efficacy of QishenYiqi combined with conventional western medicine in treating CHF were widely searched in electronic databases, including PubMed, Cochrane Library, EMBASE, CBM, CNKI, Read-show database, VIP database, and WanFang up to December 26, 2020.
The methodological quality of each trial was assessed according to the Cochrane Reviewers' Handbook 5.0.
Meta-analysis was performed by using Review Manager 5.3. Results Twenty-one RCTs (N = 2162) that met the criteria were included in the review for the assessment of methodological quality.
Meta-analysis showed that compared with the conventional western medicine (control group), QishenYiqi combined with conventional Western medicine (experience group) significantly improved clinical efficiency, left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), left ventricular ejection fraction (LVEF), brain natriuretic peptide level (BNP), 6 min-walk distance (6-MWD), and adverse reactions.
Conclusion: QishenYiqi combined with conventional western medicine are better than conventional western medicine alone to improve the indicators of patients with CHF, which provides a certain basis for the treatment of CHF.
* The products and/or claims made about specific products found on this website have not been evaluated by the United States Food and Drug Administration, and are not intended to diagnose, cure or prevent disease. The information presented on this site, including reports of clinical studies of key product ingredients, is for educational purposes only and is not intended to replace advice from your physician or other health care professional or any information found on any product label or packaging. You should always consult with a qualified health care professional before starting any exercise, diet or supplement regimen.
Feedback From Our Customers
NatureKue CardioSupport Helps Heart Healthy Daily!
CLIENTS WHO BOUGHT THIS ALSO BOUGHT
Recently viewed